NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Charles Wang of Loma Linda University to Speak at Single Cell Mtg on May 22-23 in Cambridge, Massachusetts - Charles Wang, Director for the Center for Genomics, and Professor of Microbiology and Molecular Genetics at Loma Linda University, to give a presentation at the Inaugural Single Cell Analysis Conference, May 22 & 23, 2014 in Cambridge, MA - GTCbio.com
Charles Wang of Loma Linda University to Speak at Single Cell Mtg on May 22-23 in Cambridge, Massachusetts

 

NewswireTODAY - /newswire/ - Monrovia, CA, United States, 2014/02/10 - Charles Wang, Director for the Center for Genomics, and Professor of Microbiology and Molecular Genetics at Loma Linda University, to give a presentation at the Inaugural Single Cell Analysis Conference, May 22 & 23, 2014 in Cambridge, MA - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Charles Wang, Director for the Center for Genomics, and Professor of Microbiology and Molecular Genetics at Loma Linda University to give a presentation titled “Single-Cell Transcriptome Analysis of Mouse Cardiomyocytes Derived Progenitor Cells,” at the Inaugural Single Cell Analysis in Cambridge, MA on May 22-23, 2014 by GTC.

Dr. Wang, MD, PhD, MPH, is Director of the Center for Genomics and a Professor in the Division of Microbiology & Molecular Genetics, School of Medicine, Loma Linda University (LLU).

He held the positions as Director of the Functional Genomics Core at City of Hope National Medical Center, Associate Professor of Medicine at the David Geffen School of Medicine at UCLA and Director of the Clinical Transcriptional Genomics Core at Cedars-Sinai Medical Center before joining LLU. Dr. Wang is a recipient of several awards, including the AACR-Bristol-Myers Squibb Young Investigator Award of the American Association for Cancer Research and the first place graduate award for Research Excellence of Society of Toxicology.

Dr. Wang serves as Editorial Board Members for the Current Stem Cell Research & Therapy, the World Journal of Stem Cells, the Frontiers, and the Single Cell Genomics & Proteomics. Dr. Wang is an expert on genomics and transcriptomics, with many high visibility peer-reviewed papers published in the high profile journals such as Nature Biotechnology, Nature Communications and PNAS. He was one of the project leaders for the FDA-led international working group/consortium on MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) projects.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Charles Wang of Loma Linda University to Speak at Single Cell Mtg on May 22-23 in Cambridge, Massachusetts

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)